In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40

Blood

Volumn 89, Issue 12, 1997, Pages 4493-4500

  Francisco, Joseph A ^b   Schreiber, George J ^b   Comereski, Chuck R ^b   Mezza, Laurence E ^b   Warner, Garvin L ^b   Davidson, Thomas J ^b   Ledbetter, Jeffrey A ^b   Siegall, Clay B ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; IMMUNOTOXIN;

ANALYTIC METHOD; ANIMAL CELL; ARTICLE; B LYMPHOCYTE ACTIVATION; BINDING AFFINITY; DENDRITIC CELL; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE TARGETING; IMMUNOHISTOCHEMISTRY; INTERNALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0030960076     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.12.4493     Document Type: Article

References (36)

1. Freedman AS, Nadler LM: Malignant lymphomas, in Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL (eds): Harrison's Principles of Internal Medicine (ed 13). New York, NY, McGraw-Hill, 1994, p 1774
2. Press OW, Eary J, Appelbaum FR, Badger CC, Bernstein ID: Radiolabeled antibody therapy of lymphoma, in Dana B (ed): Malignant Lymphomas, Including Hodgkin's Disease: Diagnosis, Management, and Special Problems. Boston, MA, Kluwer Academic, 1993, p 127
3. Palackdharry CS: The epidemiology of non-Hodgkin's lymphoma: Why the increased incidence? Oncology 8:67, 1994
4. Pearce N, Bethwaite P: Increasing incidence of non-Hodgkin's lymphoma: Occupational and environmental factors. Cancer Res 52s:5496, 1992
5. Devesa SS, Fears T: Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res 52s:5432, 1992
6. Grossbard ML, Nadler LM: Immunotoxin therapy of lymphoma. Cancer Treat Res 68:111, 1993
7. Brinkmann U, Pastan I: Immunotoxins against cancer. Biochim Biophys Acta 1198:27, 1994
8. Pasqualucci L, Flenghi L, Terenzi A, Bolognesi A, Stirpe F, Bigerna B, Falini B: Immunotoxin therapy of hematological malignancies. Haematologica 80:546, 1995
9. Vitetta ES, Stone M, Amlot P, Fay J, May R, Till M, Newman J, Clark P, Collins R, Cunningham D, Ghetie V, Uhr JW, Thorpe PE: Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 51:4052, 1991
10. Grossbard ML, Gribben JG, Freedman AS, Lambert JM, Kinsella J, Rabinowe SN, Iliseo L, Taylor JA, Blattler WA, Epstein CL, Nadler LM: Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood 81:2263, 1993
11. Francisco JA, Gilliland LK, Stebbins MR, Norris NA, Ledbetter JA, Siegall CB: Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen. Cancer Res 55:3099, 1995
12. Paulie S, Ehlin-Henriksson B, Mellstedt H, Koho H, Ben Aissa H, Perlmann P: A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes. Cancer Immunol Immunother 20:23, 1985
13. Clark EA, Ledbetter JA: Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc Natl Acad Sci USA 83:4494, 1986
14. Uckun FM, Gajl-Peczalska K, Myers DE, Jaszcz W, Haissig S, Ledbetter JA: Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. Blood 76:2449, 1990
15. O'Grady JT, Stewart S, Lowrey J, Howie SEM, Krajewski AS: CD40 expression in Hodgkin's disease. Am J Pathol 144:21, 1994
16. Pellat-Deceunynck C, Bataille R, Robillard N, Haroussequ J-L, Rapp M-J, Juge-Morineau N, Wijdenes J, Amiot M: Expression of CD28 and CD40 in human myeloma cells: A comparative study with normal plasma cells. Blood 84:2597, 1994
17. Hollenbaugh D, Mischel-Petty N, Edwards CP, Simon JC, Denfeld RW, Kiener PA, Aruffo A: Expression of functional CD40 by vascular endothelial cells. J Exp Med 182:33, 1995
18. Karmann K, Hughes CCW, Schechner J, Fanslow WC, Pober JS: CD40 on human endothelial cells: Inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA 92:4342, 1995
19. Caux C, Massacrier C, Vanbervliet B, Dubois B, Van Kooten C, Durand I, Banchereau J: Activation of human dendritic cells through CD40 cross-linking. J Exp Med 180:1263, 1994
20. Galy AHM, Spits H: CD40 is functionally expressed on human thymic epithelial cells. J Immunol 149:775, 1992
21. Alderson MR, Armitage RJ, Tough TW, Strockbine L, Fanslow WC, Spriggs MK: CD40 expression by human monocytes: Regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med 178:669, 1993
22. Kiener PA, Moran-Davis P, Rankin BM, Wahl AF, Aruffo A, Hollenbaugh D: Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol 155:4917, 1995
23. Yellin MJ, Winikoff S, Fortune SM, Daum D, Crow MK, Lederman S, Chess L: Ligation of CD40 on fibroblasts induces CD54 (ICAM-1) and CD106 (VCAM) up-regulation and IL-6 production and proliferation. J Leuk Biol 58:209, 1995
24. Francisco JA, Kiener PA, Moran-Davis P, Ledbetter JA, Siegall CB: Cytokine activation sensitizes human monocytic and endothelial cells to the cytotoxic effects of an anti-CD40 immunotoxin. J Immunol 157:1652, 1996
25. Johnsson B, Löfås S: Immobilization of proteins to a carboxymethyldextran modified gold surface for biospecific interaction analysis in surface plasmon resonance. Anal Biochem 145:229, 1991
26. Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A: A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci USA 89:6550, 1992
27. Friedman PN, Chace DF, Trail PA, Siegall CB: Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts. J Immunol 150:3054, 1993
28. Clark EA, Shu G, Ledbetter JA: Role of the Bp35 cell surface polypeptide in human B-cell activation. Proc Natl Acad Sci USA 82:1766, 1985
29. Ling NR, MacLennan ICM, Mason DY: B-cell and plasma cell antigens: New and previously defined clusters, in McMichael AJ (ed): Leucocyte Typing III: White Cell Differentiation Antigens. Oxford, UK, Oxford, 1987, p 302
30. Reiter Y, Brinkmann U, Jung S-H, Lee B, Kasprzyk PG, King CR, Pastan I: Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. J Biol Chem 269:18327, 1994
31. Ghetie M-A, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES: Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice. Int J Cancer 45:481, 1990
32. Kawata A, Yoshida M, Okazaki M, Yokota S, Barcos M, Seon BK: Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: Marked difference between the SCID and nude models in the antitumor efficacy of monoclonal antibody. Cancer Res 54:2688, 1994
33. Huang Y-W, Richardson JA, Tong AW, Zhang B-Q, Stone MJ, Vitetta ES: Disseminated growth of human multiple myeloma cell line in mice with severe combined immunodeficiency disease. Cancer Res 53:1392, 1993
34. Braslawsky GR, Edson MA, Pearce W, Kaneko T, Greenfield RS: Antitumor activity of adriamycin (hydrazone-linked) immunoconjugates compared with free adriamycin and specificity of tumor cell killing. Cancer Res 50:6608, 1990
35. Siegall CB, Liggitt D, Chace D, Tepper MA, Fell HP: Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity. Proc Natl Acad Sci USA 91:9514, 1994
36. Clark EA, Draves KE: Activation of macaque T cells and B cells with agonistic monoclonal antibodies. Eur J Immunol 17:1799, 1987